Journal of Psychopharmacology

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

SAGETRACK

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goodwin, G. M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Goodwin, G. M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Psychopharmacology, Vol. 6, No. 2 suppl, 312-317 (1992)
DOI: 10.1177/0269881192006002051

The effects of treatment on mortality in affective illness

Guy M. Goodwin

MRC Brain Metabolism Unit, Royal Edinburgh Hospital, Edinburgh EH10 5HF, UK

All studies of mortality in patients with a diagnosis of affective illness agree that the death rate is increased. The excess mortality appears primarily to result from suicide; any excess mortality from physical illness, most notably cardiovascular disease, now appears unlikely to be a simple consequence of affective illness. Historical comparisons suggest that acute treatment of affective disorder reduces the immediate risk of death. It is much more difficult to assess the impact of treatment upon the subsequent rates of suicide. This is true of all aspects of the acute and short-term continuation of treatment for an episode of illness, from the need for hospital admission to the choice of drug treatment. Adequate treatment of refractory depression and the possibility that some actions of drugs may increase the risks of suicide are emergent therapeutic issues that are still providing more questions than answers. Prophylaxis should also reduce the risk of suicide. However, although standardized mortality rates, reflecting relative risk, are very high, only ~2% of patients with affective disorder will commit suicide in a follow-up interval of 2 years. Comparison of mortality data for patients on lithium registers with that from lithium clinics shows important reductions in specialized clinics. Indeed, mortality from suicide may actually be lower than expected. It raises the question of whether long- term hospital follow-up by personnel with a specialist interest in drug treatment of major mental illness is safer than a potentially more erratic provision of care in the community. The future issues in the prevention of suicide include whether to treat patients by admission to a hospital in-patient unit or not, whether to treat for at least a year with adequate doses of tricyclic drugs or a selective 5-hydroxytryptamine (5-HT, serotonin) re-uptake inhibitor, and whether to maintain patients with a second episode of affective illness or a prolonged first illness indefinitely with lithium or antidepressants.

Key Words: affective disorder • mortality • suicide • antidepressants • lithium


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?